07:34 AM EDT, 05/05/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) on Monday reported the most recent data from its Phase 1/2 Tuscany trial in four newly diagnosed acute myeloid leukemia (AML) patients.

The patients are being dosed with a 40 mg or 80 mg dose of Aptose's candidate tuspetinib together with standard of care dosing of the anti-cancer drugs venetoclax and azacitidine. The regimen is being developed to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy, the company said.

Preliminary results show three of the four patients, who were dosed earlier this year, continuing treatment, with all three achieving complete remission. The fourth patient was discontinued due to lack of response to the regimen.

Three newly-diagnosed patients are now receiving the 80 mg dose of tuspetinib as part of the triple drug combination.

"The treatment paradigm for AML is shifting to triplet combination therapy," said Rafael Bejar, chief medical officer. "We have always maintained that tuspetinib, with its notable safety profile and ability to treat the larger, difficult-to-treat AML populations with high-risk mutations, could be an ideal drug for a triplet combination therapy in the frontline setting. With the majority of patients already achieving complete responses -- including early responses in patients with adverse mutations -- the clinical findings to date are bearing that out."

The data is being presented today at the Bloom Burton Healthcare Investor Conference.